Pyrrolobenzodiazepine-dimers (PBD-dimers) are DNA alkylators which exhibit extremely potent cytotoxic activities against multiple cancer cell lines (Jeffrey et al., 2013) . These molecules function by covalently binding to the 2-amino groups of guanine in the minor grooves of cellular DNA thereby forming DNA adducts that disrupt normal cell functions (Jenkins et al., 1994; Thurston and Bose, 1994; Gregson et al., 2001 ). We previously reported that an antibody drug conjugate (ADC) that combines a PBD-dimer payload, an anti-CD22 THIOMAB™ antibody, and a cyclobutyl-containing disulfide linker (1) with a drug-to-antibody ratio of 2 (DAR2) showed tumor reduction against CD22-expressing xenograft tumor models compared to the corresponding inactive ADC that utilizes a cyclopropyl-containing disulfide linker (2) in such assessments (Zhang et al., 2016a) . In these experiments, a much lower level of the free PBD-dimer 3 released from 1 was observed in tumors relative to the amount of the free cyclopropyl thiol 4, a non-immolation catabolite, produced via intracellular catabolism of 2 (several folds, Table 1A , Figures 1A and B, Zhang et al., 2016a) . We suspected that the measured quantity of the released PBD-dimer 3 in tumors might be underestimated given the known ability of PBD-dimer 3 to covalently bind to DNA and became "trapped' in a form that was not easily quantifiable (Zhang et al., 2016a) . In contrast, cyclopropyl thiol 4 did not meaningfully bind to DNA and the higher intratumor levels noted for this analyte relative to PBD-dimer 3 presumably reflect the difference in their DNA binding (Zhang et al., 2016b) . In this study, the quantity of PBD-dimer in tumors and normal tissues was determined via DNA isolation and then release of PBD-dimer from the PBD-DNA adducts. We envisioned that use of this new assay would provide a less biased
evaluation of the intracellular PBD-dimer distribution differences between tumors and normal organs following ADC administration. The amount of PBD-DNA adducts inside tumor cells should provide a better indicator of efficacy than the amount of free PBDdimer (biomarker). Moreover, characterization of the covalently bound drug may provide a better correlation of DNA alkylator concentrations with pharmacological/toxicological effects to support ADC preclinical studies.
Results
DNA was isolated from the homogenates of tumor and major organ tissues of xenograft mice treated with ADCs 1 and 2. Digestion by nuclease P1 converted the isolated DNA to single nucleotides and thus abrogated the interaction and binding affinity between PBD-dimer 3 and the minor groove of DNA ( Figure 1C ) (Shimelis and Giese, 2006; Rahman et al., 2011) . The covalent bonds between PBD-dimer 3 and the 2-amino groups of guanine were subsequently cleaved by heating of the sample following nuclease digestion (Rahman et al., 2011) . Under these sample processing conditions, PBD-dimer 3 was stable. PBD-dimer 3 was consequently recovered quantitatively from DNA-adducts and then accurately quantitated by LC-MS/MS. As shown in Table 1B, very high levels of PBD-dimer 3 were recovered from isolated tumor DNA following ADC 1 dosing to xenograft mice. At 24 and 94 h time points, these values respectively represent 98% and 99% of total PBD-dimer in tumor tissues (total = free 3 from Table   1A plus DNA-bound 3 from Table 1B ). In other words, the amount of DNA-bound 3 in tumors was approximately 40-fold higher than the corresponding free levels at 24 h, and about 120-fold higher when measured at 96 h. Somewhat reduced bound/free ratios of 3 (3-10-fold) were observed in liver and lung following treatment with ADC 1, but the
majority of PBD-dimer quantified in these tissues was still detected in the DNA-bound form (representing 78-89%) (Tables 1A and 1B) . Collectively, these data indicate that most of PBD-dimer 3 payload released from ADC molecules in tumors and other tissues is sequestered via covalent binding to DNA, which should be considered as a disposition mechanism of PBD-dimer 3. PBD-dimer is an excellent agent which rapidly alkylates DNA in vitro (Thurston and Bose, 1994; Zhang et al., 2016b) ; its predominant distribution in DNA (forming covalent adducts) indicated that the same reaction occurred efficiently in vivo.
In contrast to the corresponding intratumor levels of free 3, the amount of DNA-bound 3 detected in tumors following administration of ADC 1 increased with time. Specifically, the measured DNA-bound levels of PBD-dimer 3 were 3-4 fold higher at 96 h relative to the level detected at 24 h (192-277 vs 64-84 pmol/g tumor tissue) (Table 1B, also compare to free levels in Table 1A ). The data suggest an accumulation of PBD-dimer in tumor DNA during this period of time and further accumulation of PBD-dimer in tumors after 96 hours can be expected with an assumption that the tumor antigen is not down regulated upon ADC treatment. Interestingly, a related, time-dependent increase in the quantity of DNA-bound 3 was not observed in liver or lung tissues, and the absolute values of detected 3 (free and DNA-bound) at both 24 and 96 h were much lower than those noted in tumors (Table 1B) . We speculate that a combination of factors may limit PBD-dimer accumulation in normal healthy tissues during these experiments including
(1) a reduced uptake of ADC 1 into non-antigen containing organs, (2) preferential disposition of the released payload drug 3 in the healthy organs such as liver and kidneys that may contain additional drug metabolism enzymes and transporters for drug
clearance from tumors, and (3) possible active DNA repair in the healthy organs (Drabløs et al., 2004; Fu et al., 2012; Kraynov et al., 2016) . For unknown reasons, the amounts of DNA-bound PBD-dimer 3 observed in kidney tissues was significantly lower (below the lower limit of quantitation) than those observed in the liver and lung.
As shown in Table 1B , a greater amount of DNA was isolated from tumors relative to the normal tissues that were analyzed (mg per gram of tissue basis). These differences may be due to genomic duplications and amplifications in the cancers that are not present in the normal cells (Habano et al., 2007; Mwakigonja et al., 2010) . The yield of isolated DNA also likely depends on how well the tissues were homogenized and related experimental operations that may be difficult to perfectly control ( correlation is yet to be established between the adduct number and the triggering of cell apoptosis events (Pepper et al., 2004 ).
Interestingly, a low level of DNA-bound PBD-dimer 3 was detected in tumors obtained from xenograft mice dosed with the cyclopropyl-containing ADC 2 despite poor release of the active payload 3 from this ADC (Zhang et al., 2016a; Zhang et al., 2016b) . It is unclear whether this observed levels of DNA-bound 3 resulted from a simple chemical trial (Pietanza et al., 2015) .
In conclusion, the isolation of DNA from tumors and normal tissues and recovery of PBD-dimer 3 from PBD-DNA adducts provided new insights into the mechanism of action of PBD-dimer-containing ADCs. Marked difference in the levels of DNA adduct formation may suggest a potential of this ADC to widen the therapeutic window of highly cytotoxic agents like a DNA alkylator. Future preclinical studies can be conducted to
help ensure that an ADC delivers adequate DNA alkylators to achieve tumor remission while simultaneously maintaining a safe level of DNA alkylation in normal organs. This example demonstrates that a thorough characterization of DNA alkylation, representing a disposition pathway of a DNA alkylator, is required for understanding the mechanism of action of an ADC carrying a DNA-alkylator payload. In this study, a robust procedure for quantification of DNA-PBD adducts and drug release was developed and applied to better understand the efficacy and tolerability of an ADC carrying a DNA-alkylating payload.
Experimental Materials and Methods
Materials: Calf thymus DNA was purchased from Rockland Immunochemicals Inc (Pottstown, PA). Nuclease P1 was purchased from Sigma. DNeasy Blood & Tissue Kit was purchased from Qiagen (Valencia, CA). All the other materials used were the same as described in the previous study (Zhang et al., 2016a ).
Animal study: The procedures in animal study were described in details previously, The free payload concentration results in tumor and liver were published previously (Zhang et al., 2016a) and were included here for comparison only. ND = Not detected. LLOQ = 0.244 nM for PBD-dimer 3 and cyclopropyl thiol 4 in tissue homogenates. DNA was isolated from 15 mg of tissue homogenates. Less than 0.01 µg DNA could be extracted from 15 µL plasma sample but no PBD-dimer 3 was detected after enzyme digestion and heating. LLOQ = 0.030 pmol for PBD-dimer 3 after DNA digestion. 
